UTRxM1-18
/ UTR Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 16, 2025
UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic
(GlobeNewswire)
- "UTRxM1-18 produced dose-dependent tumor regression, 100% complete pathological responses at the highest tested dose, and significant inhibition of liver, lung, and brain metastases in preclinical pancreatic cancer models....UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals."
New P1 trial • Preclinical • Pancreatic Cancer
May 08, 2025
UTR Therapeutics Inc Announces IND submission to the US FDA for a First-in-Human Clinical Trial of an mRNA destabilizing drug targeting c-MYC driven cancers
(GlobeNewswire)
- "UTR Therapeutics...is pleased to announce a new milestone, the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for UTRxM1-18, a novel therapeutic approach for targeting c-MYC driven cancers....UTRxM1-18 harnesses UTR’s proprietary Ultra-Targeted RNA platform to degrade disease-causing transcripts with ultra-high precision and specificity....Our first-in-human Phase 1 trial is slated for 2026, pending FDA approval."
IND • New P1 trial • Solid Tumor
1 to 2
Of
2
Go to page
1